The COVID-19 pandemic has brought to the fore the fact that pharmaceutical companies with products on the EU market depend to a large extent on non-EU sources for starting materials, reagents, intermediates and active pharmaceutical ingredients (API). Temporary lockdowns of manufacturing sites as well as export bans, stockpiling and increased demand for medicines used to treat COVID-19 patients are examples of factors that can put enormous and highly variable stresses on a pharmaceutical company’s global supply chain. To mitigate COVID-19-related medicinal product shortages, the European authorities have put in place a number of initiatives and an unprecedented level of coordinated responses. These measures are very regularly updated, and pharmaceutical companies with products on the EU market are well advised to monitor developments closely.
Sidley Austin LLP provides this information as a service to clients and other friends for educational purposes only. It should not be construed or relied on as legal advice or to create a lawyer-client relationship. Readers should not act upon this information without seeking advice from professional advisers.
Attorney Advertising—Sidley Austin LLP, One South Dearborn, Chicago, IL 60603. +1 312 853 7000. Sidley and Sidley Austin refer to Sidley Austin LLP and affiliated partnerships, as explained at www.sidley.com/disclaimer.
© Sidley Austin LLP